Replidyne makes more staff cuts
This article was originally published in Scrip
Replidyne is again cutting its staff numbers by around 80% to just five employees, and will suspend the development of REP3123, for the treatment of Clostridium difficileinfection. Replidyne estimated that it would incur $3.1 million of costs related to the restructuring, $1.6 million of which is expected to be paid in employee severance benefits. The company expects to implement the staff cuts in September and October.